Partner 12 - Commissariat à l'Energie Atomique - Centre National de Genotypage

The National Centre for Genotyping aims to advance research of the genetics of human diseases through internal and collaborative research programmes in a wide variety of human diseases (cancer, metabolic disorders, and inflammatory diseases). To achieve this CNG has developed a number of state-of-the-art genomics technology platforms and laboratories.In 2002, the CNG became part of the National Consortium of Genomics Research, of which the Atomic and Alternative Energies Commission (CEA) is a member. The CEA is a leader in research, development and innovation and strives, through its laboratories, to provide the health sector with the full benefit of the technological processes developed in the nuclear field.CEA-CNG will be involved in several aspects of the CEED3 project; in particular the re-sequencing of a number of genes knows to be involved in monogenic forms of type 2 diabetes. The team aim to establish prevalence data in patients that may otherwise be misclassified.The research group for the CEED3 project at CEA-CNG is led by Dr Jorg Hager, who has extensive experience in the molecular genetics of metabolic disorders and is Head of Human Genetics at the CEA-Genomics Institute in Evry.Dr Jorg HagerCentre National de Génotypage, Commissariat à l’énergie atomique et aux energies alternatives Centre National de Génotypage